|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-12-22
|
|
pubmed:abstractText |
Experimental and clinical studies have shown that a novel symbiotic (known as SCM-III) exerts a beneficial effect on gut translocation and local and systemic inflammatory and microbial metabolic parameters. The present investigation was a preliminary trial on the effectiveness of SCM-III for irritable bowel syndrome (IBS).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1443-9611
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
169-74
|
|
pubmed:dateRevised |
2006-4-13
|
|
pubmed:meshHeading |
pubmed-meshheading:15612887-Adult,
pubmed-meshheading:15612887-Aged,
pubmed-meshheading:15612887-Bacteria,
pubmed-meshheading:15612887-Bifidobacterium,
pubmed-meshheading:15612887-Constipation,
pubmed-meshheading:15612887-Feces,
pubmed-meshheading:15612887-Female,
pubmed-meshheading:15612887-Humans,
pubmed-meshheading:15612887-Intestines,
pubmed-meshheading:15612887-Irritable Bowel Syndrome,
pubmed-meshheading:15612887-Lactobacillus acidophilus,
pubmed-meshheading:15612887-Male,
pubmed-meshheading:15612887-Middle Aged,
pubmed-meshheading:15612887-Probiotics,
pubmed-meshheading:15612887-Single-Blind Method,
pubmed-meshheading:15612887-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome.
|
|
pubmed:affiliation |
TMC Hospital, Shizuoka, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
